All News
Diffuse Cutaneous Systemic Sclerosis: Results of the SCOT Trial
Diffuse cutaneous systemic sclerosis (dcSSc) is one of the most difficult autoimmune diseases to treat. In case of major organ involvement (lung, kidney), prognosis is poor and treatment options are limited.
Read Article
Ustekinumab Effective and Safe in Crohn's Colitis
The New England Journal of Medicine has reported the results of a large clinical trial demonstrating the efficacy of ustekinumab (Stelara) in treating patients with active Crohn's disease (CD). (Citation source http://buff.ly/2gsSNcs)
Read Article
Maintenance of Remission in ANCA-vasculitis: MAINRITSAN study.
It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.
Read Article
Epilepsy is More Likely in Offspring for Women with Rheumatoid Arthritis
The offspring of women with rheumatoid arthritis (RA) may be at greater risk for the development of epilepsy, according to a recent report in the journal Neurology, suggesting that epileptogenic triggers may begin during pregnancy and may be wors
Read Article
Three Year Data on Secukinumab
Dr. Philip Mease, MD presented the long-term efficacy and safety data for secukinumab in psoriatic arthritis (PsA) at the ACR Annual meeting in Washington, DC.
Read Article
My ACR 2016 Highlights
Washington is always a great city to visit (even though there were a few protesters floating around the streets). I hope the posts I made were of interest to some readers. Here are my top 5 highlights from ACR 2016:
Read Article
ACR16 Day 4 Ends with Rheumatology Roundup
The final day of the 2016 annual ACR meeting saw the return of "Rheumatology Round-up" at 7:30am in Hall D.
Read Article
Dual Cytokine Inhibition for RA
The notion of a single biologic targeting two cytokines is intriguing. ABT-122 is a new dual-variable domain immunoglobulin that neutralizes both TNF-α and IL-17A.
Read Article
The Spirit of ACR 2016
All week I’ve attempted to catch the spirit of ACR and rheumatology in a picture or quote, but after attending ACR 2016 in Washington, DC, I found myself surrounded by examples.
Read Article
ACR 2016 – Day 3 Highlights
Some big highlights from Tuesday at the 2016 ACR/ARHP annual meeting included the PRECISION trial, EXXELERATE trial and the new anti-IL-23 in psoriatic arthritis.
Read Article
Celecoxib Shines and Naproxen Tanks in the PRECISION Study
The PRECISION trial was published this week in the NEJM, presented at the Cardiology meetings in New Orleans, and presented today by Dr. Daniel Solomon at the 2016 ACR annual meeting in Washington, D.C. (citation source http://buff.ly/2fUmoqO)
Read Article
Diffuse Cutaneous Systemic Sclerosis: Results of the SCOT Trial
Diffuse cutaneous systemic sclerosis (dcSSc) is one of the most difficult autoimmune diseases to treat. In case of major organ involvement (lung, kidney), prognosis is poor and treatment options are limited.
Read Article
Guselkumab Efficacy and Tolerability in PsA/PsO
New treatment options for psoriatic arthritis continue to be explored at this year’s ACR/ARHP Annual Meeting in Washington, DC. Guselkumab (GUS) is a fully human monoclonal antibody against the p19 subunit of IL-23.
Read Article
Tocilizumab Infections Less in ACPA+ Patients
Tocilizumab is in the spotlight at this year’s ACR 2016 meeting but there is still much to learn, including more about its safety profile. In an abstract presented at today’s poster session (Abstract 2618), Morel, et al.
Read Article
ACR 2016 – Day 2 Highlights
Big highlights from Monday included the Hench Lecture, plenary session abstracts and presentations on drug safety and cost efficacy in rheumatoid arthritis.
Read Article
Maintenance of Remission in ANCA-vasculitis: MAINRITSAN study.
It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.
Read Article
Herpes Zoster and Giant Cell Arteritis
The potential association of herpes zoster with giant cell arteritis (GCA) has been a debated topic and certainly has gotten some attention at ACR 2016 this year.
Read Article
MACRA: Not Just an Acronym Inside an Acronym
Education on MACRA is the key to successful survival. The important take home points noted in Dr. Will Harvey’s lecture at ACR 2016 (session title: Holy MACRA! How to Survive and Thrive in the New Era of MACRA, MIPS, and APMs) are stated below.
Read Article
ACR 2016 – Day 1 Highlights
The annual ACR meeting began last night with a number of famed rheumatologists being inducted as ACR Masters.
Read Article